BRAF


Also found in: Acronyms.

BRAF

A gene on chromsome 7q34 that encodes a protein of the raf/mil family of serine/threonine protein kinases, which plays a role in regulating the MAP kinase/ERKs-signalling pathway, affecting cell division, differentiation and secretion.

Molecular pathology
BRAF mutations are associated with cardiofaciocutaneous syndrome, which is characterised by heart defects, mental retardation and a distinctive facial appearance. Acquired BRAF mutations have been linked to non-Hodgkin lymphoma, colorectal cancer, melanoma, thyroid carcinoma, non-small cell lung carcinoma and adenocarcinoma of lung.
References in periodicals archive ?
Cotellic in combination with Zelboraf is now approved in the EU and Switzerland for the treatment of people with BRAF V600 mutation-positive advanced melanoma.
trametinib) for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test.
a 2009 Stand Up To Cancer Innovative Research Grant recipient, and their colleagues identified a fusion between two genes, PAPSS1 and BRAF, which they called PAPSS1-BRAF.
The BRAF V600E (VE1) IHC in vitro diagnostic is a valuable addition to our assay portfolio to aid physicians and patients in the important stratification of colon cancer.
Activating mutations in the BRAF oncogene occur in 10%-15% of colorectal cancers, and are thought to play a role in the upregulation and synthesis of certain prostaglandins.
BRAF mutations have been reported to occur in 40% to 70% of melanoma cases, most often affecting codon 600 (reviewed in Ribas and Flaherty (7)).
The cobas BRAF test will play a critical role in improving treatment for metastatic melanoma, one of the most aggressive and deadly cancers.
Our study shows that the genetic damage of BRAF is the first step in skin cancer development.
The V600E mutant form of BRAF kinase in particular has
1] gene somatic variations have been found in a high proportion (40%-88%) of malignant melanoma tissue (1-9) and also are common in benign nevi (6,10), a finding that may suggest that BRAF variations play a role in the initiation of melanocytic neoplasia.
Tokyo, Japan, Feb 13, 2006 - (JCN) - The Tohoku University Graduate School of Medicine has discovered that two different oncogenes KRAS and BRAF play a key role in the occurrence of cardiofaciocutaneous (CFC) syndrome.
A team of researchers from the University Hospital of Tubingen, Germany, has shown that genetic variations in BRAF, a gene previously implicated in malignant melanoma, could account for a substantial proportion of the so-called sporadic form of the disease.